Effects of hydroxyurea on brain function in children with sickle cell anemia
- 31 July 2021
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (10) , e29254
Abstract
Introduction: Sickle cell anemia (SCA) results in numerous adverse effects on the brain, including neurocognitive dysfunction. Hydroxyurea has been utilized extensively for management of SCA, but its effects on brain function have not been established.Methods: We examined prospectively the effects of 1 year of treatment with hydroxyurea on brain function in children with SCA (HbSS/HbSβ0‐thalassemia) by baseline and exit evaluations, including comprehensive neurocognitive testing, transcranial Doppler ultrasound (TCD), and brain MRI (silent cerebral infarcts [SCI], gray matter cerebral blood flow [GM‐CBF], and blood oxygen level‐dependent [BOLD] signal from visual stimulation).Results: Nineteen patients with SCA, mean age 12.4 years (range 7.2–17.8), were evaluated. At baseline, subjects had these mean values: full‐scale IQ (FSIQ) 82.8, TCD velocity 133 cm/s, GM‐CBF 64.4 ml/100 g/min, BOLD signal 2.34% increase, and frequency of SCI 47%. After 1 year of hydroxyurea, there were increases in FSIQ (+2, p = .059) and reading passage comprehension (+4, p = .033), a significant decrease in TCD velocity (−11 cm/s, p = .007), and no significant changes in GM‐CBF, BOLD, or SCI frequency. Hemoglobin F (HbF) was associated with passage comprehension, hemoglobin with lower TCD velocity, and lower GM‐CBF with greater working memory. Higher BOLD signal was associated with higher processing speed and lower TCD velocity with higher math fluency.Discussion: Improvements in neurocognition and decreased TCD velocity following 1 year of treatment support hydroxyurea use for improving neurocognitive outcomes in SCA. Understanding the mechanisms of benefit, as indicated by relationships of neurocognitive function with HbF, hemoglobin, and CBF, requires further evaluation.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- Association between hydroxycarbamide exposure and neurocognitive function in adolescents with sickle cell diseaseBritish Journal of Haematology, 2020
- Cognitive Function in Sickle Cell Disease Across Domains, Cerebral Infarct Status, and the Lifespan: A Meta-AnalysisJournal of Pediatric Psychology, 2019
- Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyureaPediatric Blood & Cancer, 2018
- Central nervous system complications and management in sickle cell diseaseBlood, 2016
- Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemiaBlood, 2015
- Parent education and biologic factors influence on cognition in sickle cell anemiaAmerican Journal of Hematology, 2013
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemiaBlood, 2007
- The Association of Oral Hydroxyurea Therapy with Improved Cognitive Functioning in Sickle Cell DiseaseChild Neuropsychology, 2007
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995